EC signs prepurchase agreement with Valneva
The European Commission has inked the pre-purchase agreement over Valnevas inactivated whole virus pandemic vaccine VLA2001 announed in mid-October.
Its the 8th contract of the European Commission with a COVID-19 vaccine producer. Under the now signed agreement, Austrian-French (Lyon/Vienna) public company Valneva SA will deliver 24.3 million doses of its whole virus vaccine VLA2001 to EU member states in Q2/2022 and Q3/2022, if the EMA recommends market approval of the vaccine, and have the option to purchase further 60 million doses in 2023.
The EC has already signed prepurchase agreements with AstraZeneca, Sanofi-GSK, Janssen Pharmaceutica NV, BioNTech-Pfizer, CureVac, Moderna and Novavax. Under the contract, EU member states have the option of donating the vaccine to low- and middle-income countries or giving it to other European countries.
According to a report of the German TV broadcaster ARD, the manufacturers can object to the transfer. However, it remains unclear why delivery problems to the Global South remained limited to vaccine Germany.
Biocytogen Co Ltd
Draupnir Bio ApS